Literature DB >> 20145172

Frequent downregulation of miR-34 family in human ovarian cancers.

David C Corney1, Chang-Il Hwang, Andres Matoso, Markus Vogt, Andrea Flesken-Nikitin, Andrew K Godwin, Aparna A Kamat, Anil K Sood, Lora H Ellenson, Heiko Hermeking, Alexander Yu Nikitin.   

Abstract

PURPOSE: The miR-34 family is directly transactivated by tumor suppressor p53, which is frequently mutated in human epithelial ovarian cancer (EOC). We hypothesized that miR-34 expression would be decreased in EOC and that reconstituted miR-34 expression might reduce cell proliferation and invasion of EOC cells. EXPERIMENTAL DESIGNS: miR-34 expression was determined by quantitative reverse transcription-PCR and in situ hybridization in a panel of 83 human EOC samples. Functional characterization of miR-34 was accomplished by reconstitution of miR-34 expression in EOC cells with synthetic pre-miR molecules followed by determining changes in proliferation, apoptosis, and invasion.
RESULTS: miR-34a expression is decreased in 100%, and miR-34b*/c in 72%, of EOC with p53 mutation, whereas miR-34a is also downregulated in 93% of tumors with wild-type p53. Furthermore, expression of miR-34b*/c is significantly reduced in stage IV tumors compared with stage III (P = 0.0171 and P = 0.0029, respectively). Additionally, we observed promoter methylation and copy number variations at mir-34. In situ hybridization showed that miR-34a expression is inversely correlated with MET immunohistochemical staining, consistent with translational inhibition by miR-34a. Finally, miR-34 reconstitution experiments in p53 mutant EOC cells resulted in reduced proliferation, motility, and invasion, the latter of which was dependent on MET expression.
CONCLUSIONS: Our work suggests that miR-34 family plays an important role in EOC pathogenesis and reduced expression of miR-34b*/c may be particularly important for progression to the most advanced stages. Part of miR-34 effects on motility and invasion may be explained by regulation of MET, which is frequently overexpressed in EOC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20145172      PMCID: PMC2822884          DOI: 10.1158/1078-0432.CCR-09-2642

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  47 in total

Review 1.  Role of p53 and Rb in ovarian cancer.

Authors:  David C Corney; Andrea Flesken-Nikitin; Jinhyang Choi; Alexander Yu Nikitin
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

2.  MicroRNAs impair MET-mediated invasive growth.

Authors:  Cristina Migliore; Annalisa Petrelli; Elena Ghiso; Simona Corso; Lorena Capparuccia; Adriana Eramo; Paolo M Comoglio; Silvia Giordano
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

3.  Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer.

Authors:  Lin Zhang; Stefano Volinia; Tomas Bonome; George Adrian Calin; Joel Greshock; Nuo Yang; Chang-Gong Liu; Antonis Giannakakis; Pangiotis Alexiou; Kosei Hasegawa; Cameron N Johnstone; Molly S Megraw; Sarah Adams; Heini Lassus; Jia Huang; Sippy Kaur; Shun Liang; Praveen Sethupathy; Arto Leminen; Victor A Simossis; Raphael Sandaltzopoulos; Yoshio Naomoto; Dionyssios Katsaros; Phyllis A Gimotty; Angela DeMichele; Qihong Huang; Ralf Bützow; Anil K Rustgi; Barbara L Weber; Michael J Birrer; Artemis G Hatzigeorgiou; Carlo M Croce; George Coukos
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-05       Impact factor: 11.205

4.  The impact of microRNAs on protein output.

Authors:  Daehyun Baek; Judit Villén; Chanseok Shin; Fernando D Camargo; Steven P Gygi; David P Bartel
Journal:  Nature       Date:  2008-07-30       Impact factor: 49.962

5.  Dicer, Drosha, and outcomes in patients with ovarian cancer.

Authors:  William M Merritt; Yvonne G Lin; Liz Y Han; Aparna A Kamat; Whitney A Spannuth; Rosemarie Schmandt; Diana Urbauer; Len A Pennacchio; Jan-Fang Cheng; Alpa M Nick; Michael T Deavers; Alexandra Mourad-Zeidan; Hua Wang; Peter Mueller; Marc E Lenburg; Joe W Gray; Samuel Mok; Michael J Birrer; Gabriel Lopez-Berestein; Robert L Coleman; Menashe Bar-Eli; Anil K Sood
Journal:  N Engl J Med       Date:  2008-12-18       Impact factor: 91.245

Review 6.  Drug development of MET inhibitors: targeting oncogene addiction and expedience.

Authors:  Paolo M Comoglio; Silvia Giordano; Livio Trusolino
Journal:  Nat Rev Drug Discov       Date:  2008-06       Impact factor: 84.694

7.  Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer.

Authors:  Dmitri Lodygin; Valery Tarasov; Alexey Epanchintsev; Carola Berking; Tatjana Knyazeva; Henrike Körner; Piotr Knyazev; Joachim Diebold; Heiko Hermeking
Journal:  Cell Cycle       Date:  2008-08-01       Impact factor: 4.534

8.  miR-34a repression of SIRT1 regulates apoptosis.

Authors:  Munekazu Yamakuchi; Marcella Ferlito; Charles J Lowenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-28       Impact factor: 11.205

9.  miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells.

Authors:  Na Li; Hanjiang Fu; Yi Tie; Zheng Hu; Wei Kong; Yongge Wu; Xiaofei Zheng
Journal:  Cancer Lett       Date:  2008-11-08       Impact factor: 8.679

10.  miRNA in situ hybridization in formaldehyde and EDC-fixed tissues.

Authors:  John T G Pena; Cherin Sohn-Lee; Sara H Rouhanifard; Janos Ludwig; Markus Hafner; Aleksandra Mihailovic; Cindy Lim; Daniel Holoch; Philipp Berninger; Mihaela Zavolan; Thomas Tuschl
Journal:  Nat Methods       Date:  2009-01-11       Impact factor: 28.547

View more
  140 in total

1.  MicroRNA 34c gene down-regulation via DNA methylation promotes self-renewal and epithelial-mesenchymal transition in breast tumor-initiating cells.

Authors:  Fengyan Yu; Yu Jiao; Yinghua Zhu; Ying Wang; Jingde Zhu; Xiuying Cui; Yujie Liu; Yinghua He; Eun-Young Park; Hongyu Zhang; Xiaobin Lv; Kelong Ma; Fengxi Su; Jong Hoon Park; Erwei Song
Journal:  J Biol Chem       Date:  2011-11-10       Impact factor: 5.157

2.  MET-dependent cancer invasion may be preprogrammed by early alterations of p53-regulated feedforward loop and triggered by stromal cell-derived HGF.

Authors:  Chang-Il Hwang; Jinhyang Choi; Zongxiang Zhou; Andrea Flesken-Nikitin; Alexander Tarakhovsky; Alexander Yu Nikitin
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

3.  Wild-type p53 controls cell motility and invasion by dual regulation of MET expression.

Authors:  Chang-Il Hwang; Andres Matoso; David C Corney; Andrea Flesken-Nikitin; Stefanie Körner; Wei Wang; Carla Boccaccio; Snorri S Thorgeirsson; Paolo M Comoglio; Heiko Hermeking; Alexander Yu Nikitin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-09       Impact factor: 11.205

4.  Downregulation of cell cycle-related proteins in ovarian cancer line and cell cycle arrest induced by microRNA.

Authors:  Jian-Mei Yuan; Xue-Jun Shi; Ping Sun; Jun-Xia Liu; Wei Wang; Ming Li; Feng-Yu Ling
Journal:  Int J Clin Exp Med       Date:  2015-10-15

5.  Multiple functional linear model for association analysis of RNA-seq with imaging.

Authors:  Junhai Jiang; Nan Lin; Shicheng Guo; Jinyun Chen; Momiao Xiong
Journal:  Quant Biol       Date:  2015-08-15

6.  A comprehensive investigation using meta-analysis and bioinformatics on miR-34a-5p expression and its potential role in head and neck squamous cell carcinoma.

Authors:  Jixi Li; Kang Liu; Tingting Zhang; Zhendong Yang; Rensheng Wang; Gang Chen; Min Kang
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

7.  Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.

Authors:  Mark Mackiewicz; Konrad Huppi; Jason J Pitt; Tiffany H Dorsey; Stefan Ambs; Natasha J Caplen
Journal:  Breast Cancer Res Treat       Date:  2011-08-04       Impact factor: 4.872

Review 8.  Understanding the CREB1-miRNA feedback loop in human malignancies.

Authors:  Ya-Wen Wang; Xu Chen; Rong Ma; Peng Gao
Journal:  Tumour Biol       Date:  2016-04-09

9.  Serum microRNA profiles among dioxin exposed veterans with monoclonal gammopathy of undetermined significance.

Authors:  Weixin Wang; Youn K Shim; Joel E Michalek; Emily Barber; Layla M Saleh; Byeong Yeob Choi; Chen-Pin Wang; Norma Ketchum; Rene Costello; Gerald E Marti; Robert F Vogt; Ola Landgren; Katherine R Calvo
Journal:  J Toxicol Environ Health A       Date:  2020-04-14

10.  miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.

Authors:  Zhaojian Liu; Elizabeth Gersbach; Xiyu Zhang; Xiaofei Xu; Ruifen Dong; Peng Lee; Jinsong Liu; Beihua Kong; Changshun Shao; Jian-Jun Wei
Journal:  Mol Cancer Res       Date:  2013-09-17       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.